Social Cognitive Training for Psychosis: Treatment Development

This study is not yet open for participant recruitment.
Verified April 2012 by Yale University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Joanna Fiszdon, Yale University
ClinicalTrials.gov Identifier:
NCT01579422
First received: April 10, 2012
Last updated: April 16, 2012
Last verified: April 2012
  Purpose

The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specifically the intentions and feelings of others.

Study methods include preliminary treatment and manual development based on series of uncontrolled cases, manual refinement, and a small feasibility/efficacy trial of the newly developed intervention.


Condition Intervention Phase
Schizophrenia
Psychosis
Behavioral: social cognitive training
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Social Cognitive Training for Psychosis: Phase I Treatment Development

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • social cognition [ Time Frame: change from baseline to approximately 6 weeks ] [ Designated as safety issue: No ]
    AIHQ Eyes Task Hinting Task IPSAQ


Estimated Enrollment: 40
Study Start Date: May 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: social cognitive training Behavioral: social cognitive training
social cognitive training, 8-10 sessions

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia or other psychotic disorder
  • Age between 18 and 55
  • Psychiatrically stable
  • Clinician agrees to individual's participation in study
  • English as primary language

Exclusion Criteria:

  • current (past 30 days) symptoms of alcohol abuse/dependence
  • developmental disability
  • severe auditory/visual impairment or known neurological disorder
  • participant has a legal conservator
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01579422

Contacts
Contact: Joanna Fiszdon, Ph.D. 203-932-5711 ext 2231 joanna.fiszdon@yale.edu

Locations
United States, Connecticut
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
  More Information

No publications provided

Responsible Party: Joanna Fiszdon, Associate Professor, Yale University
ClinicalTrials.gov Identifier: NCT01579422     History of Changes
Other Study ID Numbers: A08405, 1R34MH090109
Study First Received: April 10, 2012
Last Updated: April 16, 2012
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by Yale University:
schizophrenia
treatment
social cognition

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on April 17, 2014